Your browser doesn't support javascript.
loading
[Temporary approval for intranasal naloxone: Setting up in a French addiction center]. / Pratique de l'ATU de cohorte de la naloxone intranasale (Nalscue®) : mise en place dans un CSAPA parisien.
Barré, Thomas; Vorspan, Florence; Fortias, Maeva; Veyrier, Marc; Cavagna, Pauline; Azuar, Julien; Nicolas, Louise; Naccache, François; Barreteau, Hélène; Bellivier, Franck; Bloch, Vanessa.
Affiliation
  • Barré T; Département de psychiatrie et de médecine addictologique, hôpital Fernand Widal, AP-HP, 200, rue du faubourg-Saint-Denis, 75010 Paris, France. Electronic address: thomas.barre@aphp.fr.
  • Vorspan F; Département de psychiatrie et de médecine addictologique, hôpital Fernand Widal, AP-HP, 200, rue du faubourg-Saint-Denis, 75010 Paris, France; INSERM UMRS-1144, 75006 Paris, France.
  • Fortias M; Département de psychiatrie et de médecine addictologique, hôpital Fernand Widal, AP-HP, 200, rue du faubourg-Saint-Denis, 75010 Paris, France.
  • Veyrier M; Pharmacie, hôpital Lariboisière Fernand-Widal, AP-HP, 75010 Paris, France.
  • Cavagna P; Pharmacie, hôpital Lariboisière Fernand-Widal, AP-HP, 75010 Paris, France.
  • Azuar J; Département de psychiatrie et de médecine addictologique, hôpital Fernand Widal, AP-HP, 200, rue du faubourg-Saint-Denis, 75010 Paris, France.
  • Nicolas L; Pharmacie, hôpital Lariboisière Fernand-Widal, AP-HP, 75010 Paris, France.
  • Naccache F; Département de psychiatrie et de médecine addictologique, hôpital Fernand Widal, AP-HP, 200, rue du faubourg-Saint-Denis, 75010 Paris, France.
  • Barreteau H; Pharmacie, hôpital Lariboisière Fernand-Widal, AP-HP, 75010 Paris, France.
  • Bellivier F; Département de psychiatrie et de médecine addictologique, hôpital Fernand Widal, AP-HP, 200, rue du faubourg-Saint-Denis, 75010 Paris, France; INSERM UMRS-1144, 75006 Paris, France.
  • Bloch V; Pharmacie, hôpital Lariboisière Fernand-Widal, AP-HP, 75010 Paris, France.
Therapie ; 73(6): 495-500, 2018 Dec.
Article in Fr | MEDLINE | ID: mdl-29680374
ABSTRACT
Intranasal naloxone aims at preventing opioid overdose related deaths in active drug users. In France, it has been available since July 2016 through a temporary approval which requires a hospital-based pharmacy and a nominative registration of each patient. We present the characteristics of the first patients who could receive this prescription in our hospital-based addiction center and how they used naloxone during follow-up. Results favor a larger dispensing of naloxone. Patients' as well as peers' and families' education is needed.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Drug Approval / Drug Overdose / Ambulatory Care Facilities / Addiction Medicine / Health Plan Implementation / Naloxone Type of study: Prognostic_studies / Risk_factors_studies / Sysrev_observational_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: Fr Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Drug Approval / Drug Overdose / Ambulatory Care Facilities / Addiction Medicine / Health Plan Implementation / Naloxone Type of study: Prognostic_studies / Risk_factors_studies / Sysrev_observational_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: Fr Year: 2018 Type: Article